Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Hologic ( (HOLX) ) is now available.
On July 15, 2025, Hologic, Inc. and its subsidiaries refinanced their term loan and revolving credit facility by entering into a Refinancing Amendment to their existing Credit and Guaranty Agreement. This amendment extends the maturity date to July 15, 2030, and provides additional financial flexibility under certain covenants, impacting the company’s operational capabilities and financial strategy.
The most recent analyst rating on (HOLX) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Hologic stock, see the HOLX Stock Forecast page.
Spark’s Take on HOLX Stock
According to Spark, TipRanks’ AI Analyst, HOLX is a Neutral.
Hologic’s solid financial health and strategic focus on non-product revenue growth provide a stable base. However, recent revenue declines, geopolitical challenges, and higher relative valuation dampen the overall outlook. Technical indicators suggest mixed momentum, requiring cautious consideration by investors.
To see Spark’s full report on HOLX stock, click here.
More about Hologic
Hologic, Inc. is a Delaware-based corporation operating in the medical technology industry. The company specializes in providing diagnostic products, medical imaging systems, and surgical products, with a focus on women’s health.
Average Trading Volume: 3,176,448
Technical Sentiment Signal: Hold
Current Market Cap: $14.23B
See more insights into HOLX stock on TipRanks’ Stock Analysis page.